Skip navigation
Cubicin: the only once daily option for MRSA — skin and bacteremia

Extends your reach against MRSA outside the hospital
  • Through March 2008, more than 500,000 patients have been treated with CUBICIN1 (estimated number of patients treated based on sales)
  • Once daily 30-minute, 50-mL infusion
  • Can be given by peripheral line, midline, or peripherally inserted central catheter
  • No required monitoring of drug level in blood

Reimbursement assistance: 1-866-RX-DAPTO (793-2786) — Select option 2
  • Permanent J-code: J0878
    • In the dialysis setting, separate reimbursement outside of composite rate
  • ICD-9-CM diagnosis codes:
    • 680.XX-686.XX (skin and subcutaneous tissue infections)
    • 998.5X (post-op infections)
    • 790.7 (bacteremia)
    • 421.XX (acute and subacute endocarditis)

ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification. ICD-9-CM is the official system of assigning codes to diagnoses and procedures associated with hospital utilization in the United States.

Demonstrated efficacy against MRSA and MSSA in the skin and blood
Proven clinical success with CUBICIN
  • In complicated skin infections—both MRSA and MSSA2
    • Clinical relapse rates were 4.2% for patients receiving CUBICIN vs 5.5% for comparators*
  • In S. aureus bacteremia—both MRSA and MSSA

CUBICIN has a distinct mechanism of action
  • Rapid bactericidal activity in vitro against MRSA and MSSA3†
  • >99% of S. aureus isolates are susceptible to CUBICIN, according to global surveillance studies4

Once daily dosing to treat complicated skin infections and S. aureus bacteremia


  • Administer after hemodialysis on hemodialysis days

Demonstrated safety against MRSA and MSSA in the skin and blood
  • Most adverse events reported with CUBICIN in clinical studies were described as mild to moderate in intensity
  • In the S. aureus bacteremia trial, CUBICIN demonstrated significantly less renal decline‡ vs dual therapy5§

* Vancomycin or semisynthetic penicillin.
† The clinical significance of in vitro data has not been established.
‡ Decreased renal function defined as a creatinine clearance level <50 mL/min if baseline clearance was 50 mL/min, or a decrease of 10 mL/min if baseline clearance was <50 mL/min.
§ Dual therapy was defined as treatment with vancomycin or a semisynthetic penicillin + 4 days of initial low-dose gentamicin.

Download the above information as a PDF
References: 1. Data on file. Cubist Pharmaceuticals, Inc. 2. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2004;38:1673-1681. 3. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:2538-2544. 4. Jones RN, Fritsche TR, Streit JM, Sader HS. Evaluation of daptomycin activity tested against 34,603 bacterial strains from hospitalized patients: summary of a 4 year surveillance program for North America and Europe (2002-2005). Poster presented at: 44th Annual Meeting of IDSA; October 12-15, 2006; Toronto, Canada. Poster 243. 5. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-665.